Fucikova J, et al. - Authors undertook this Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA (prostate-specific antigen) after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. They realized that long-term immunotherapy of prostate cancer patients experiencing early signs of PSA recurrence using DCVAC/PCa was safe, induced an immune response and led to the significant prolongation of PSA doubling time (PSADT). In patients with biochemical recurrence of the prostate cancer, long-term follow-up could show whether the changes in PSADT might improve the clinical outcome.